Building For a Transformative Future
From our start in Beijing in 2010, with a handful of entrepreneurial scientists and developers…
…to today, with a global team across five continents, including over 1,000 in the United States and hundreds in Europe and Australia, driving a rich pipeline and high-value commercial medicines…
…we are united by a shared passion for discovering and developing potential new medicines and improving access to them.
And we’re just getting started.
2010
2010
Founded as a research and development company
2011
2011
Initiated discovery programs at our first R&D center, in Beijing
2012
2012
Initiated PD-1 and BTK discovery programs
2013
2013
Started first clinical development in Australia
2014
2014
Began clinical development of pamiparib and zanubrutinib
2015
2015
Opened first U.S. office (Massachusetts)
2016
2016
Completed Nasdaq IPO
2017
2017
Became a commercial-stage company in China with medicines in-licensed from Celgene (now part of BMS); initiated the first global Phase 3 registrational trial of zanubrutinib; completed construction of first manufacturing facility in Suzhou, China
2018
2018
Completed dual primary listing on the Hong Kong Stock Exchange; established presence in Europe; secured our first China national reimbursement
2019
2019
Received first global approval, in the U.S., for BRUKINSA® (zanubrutinib); received first global approval, in China, for tislelizumab; entered global strategic collaboration with Amgen; completed first biologics manufacturing plant in Guangzhou, China
2020
2020
Received first approvals for BRUKINSA® in China; received additional approvals in China for tislelizumab; secured national reimbursement in China for tislelizumab, BRUKINSA®, and an in-licensed medicine; established additional R&D center in Shanghai
2021
2021
Entered global strategic collaborations with Novartis for tislelizumab and ociperlimab; received approvals in the U.S. for additional indications of BRUKINSA®’s; received first approval in the EU and UK for BRUKINSA®; acquired a 42-acre site near Princeton, N.J. for a biologics manufacturing plant and clinical R&D center; completed third stock exchange listing, on the STAR Market of the Shanghai Stock Exchange